Delivery Order SPE2DB22D3009-SPE2DB25FBB97
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Everolimus 0.75 mg tablets (60-count) with a ceiling value of $6,624.37. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion by August 11, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child order under a larger vehicle and carries no set-aside designation. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Everolimus 5 mg tablets in quantities of 30 units, with a ceiling value of $19,375.40. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is set for ultimate completion on July 23, 2025, with performance being executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $3,978.63 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Everolimus 1 mg tablets in unit dose packaging (60 count). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 31, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Everolimus 1 mg tablets in unit dose packaging (60 count) under a firm fixed-price contract valued at $10,949.64. This delivery order, which is a child award under AmerisourceBergen's broader contract vehicle, represents a competitive award with no set-aside designation and is scheduled for completion by August 20, 2025. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Everolimus 5 mg tablets (30-count packages) with a ceiling value of $44,765.09. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 13, 2025. The award is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,856.17 to AmerisourceBergen Drug Corp for the supply of Everolimus 1 mg tablets (60-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation, representing a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery order carries an ultimate completion date of August 12, 2025, with performance occurring at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Everolimus 2.5 mg tablets in unit dose packaging (28-count) with a ceiling value of $1,095.33. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,927.99 firm fixed-price contract is for the delivery of Everolimus 10 mg tablets, a medication used to treat certain medical conditions. The contract has an ultimate completion date of April 18, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC)...
- This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of Everolimus 10 mg tablets. The award has a ceiling value of $6,791.30 and a completion date of June 11, 2025. The contract is a firm-fixed-price delivery order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Everolimus 0.25 mg tablets. The contract has a firm fixed price of $4,509.77 and a period of performance through April 23, 2025. It is not a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBB97Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Everolimus 1 mg tablets (60-count) with a ceiling value of $16,540.67. This firm fixed-price delivery order is not set-aside and represents a competitive award to the prime contractor. The contract is set to be completed by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems through the Defense Logistics Agency. The company's expansive IDC vehicle enables it to supply a comprehensive portfolio of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency and other federal healthcare customers globally. Everolimus, an immunosuppressant and anti-cancer medication, represents one of the specialized pharmaceutical products within the company's extensive federal medical supply portfolio delivered through competitively awarded delivery orders with firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.5k | 7/28/25 |